Auxilium

Press Releases

Keyword Search
 

Below please find a listing of the most recent Auxilium press releases.

DateTitle 
Oct 30, 2014Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
$109.6 Million in 3Q 2014 Net Revenues Driven by Strong XIAFLEX Growth; Company Returns to Profitability with 3Q Non-GAAP EPS of $0.27 per Share CHESTERBROOK, Pa., Oct. 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quart... 
Printer Friendly Version
Oct 20, 2014Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same ha... 
Printer Friendly Version
Oct 9, 2014Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion
- Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth - Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business - Transaction Expected to be Immediately Accretive - Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Milli... 
Printer Friendly Version
Sep 22, 2014Auxilium Provides Transaction Update
Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board") has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo") and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under... 
Printer Friendly Version
Sep 18, 2014Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting
Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution ... 
Printer Friendly Version
Sep 18, 2014VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a... 
Printer Friendly Version
Sep 17, 2014Auxilium Responds To Unsolicited Proposal From Endo International
Adopts One Year Stockholder Rights Plan CHESTERBROOK, Pa., Sept. 17, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today confirmed that Auxilium has received an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ENDP) to acquire all of the outstanding shares of Auxilium common stock at a price of $28.10 per share in cash and Endo stock, subject to due diligence, financing and other conditions. A copy of the uns... 
Printer Friendly Version
Sep 9, 2014Auxilium Pharmaceuticals, Inc. Announces Corporate Restructuring Designed To Streamline Operations, Maximize Cash Flow And Drive Sustainable Earnings Growth
- Expected to Reduce Annual Operating Expenses by At Least $75 Million - - Focus on Targeted R&D Spend, Consolidated Commercial Operations, Improved Manufacturing Efficiency and Streamlined G&A Expenses - CHESTERBROOK, Pa., Sept. 9, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced steps it is taking to reduce its costs and more fully support the Company's goal to drive earnings growth and build shareholder ... 
Printer Friendly Version
Aug 28, 2014Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting
Study Results of Concurrent CCH Injections to Treat Two Dupuytren's Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment of Two Affected Joints Concurrently CHESTERBROOK, Pa. , Aug. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from trials evaluating the use of collagenase clostridiu... 
Printer Friendly Version
Aug 27, 2014Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference
CHESTERBROOK, Pa., Aug. 27, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Morgan Stanley Healthcare Conference to be held September 8-10, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 10:55 a.m. ET on Wednesday, September 1... 
Printer Friendly Version
Aug 21, 2014Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., Aug. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibroscl... 
Printer Friendly Version
Aug 11, 2014Auxilium Pharmaceuticals, Inc. Appoints Andrew Saik Chief Financial Officer
CHESTERBROOK, Pa., Aug. 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced that Andrew Saik will be appointed Chief Financial Officer, effective August 18, 2014. Mr. Saik will be responsible for all financial and information technology activities and relationships and will play a critical leadership role in executing Auxilium's diversification and growth strategy.   "Andrew brings nearly 20 years of hands-o... 
Printer Friendly Version
Aug 7, 2014Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
2Q 2014 Net Revenues of $83.0 Million Driven by Launches of XIAFLEX for Peyronie's Disease and STENDRA Auxilium Continues Strategic Transformation into Leading North American Specialty Biopharmaceutical Company with QLT Inc. Merger Expected to Close in 4Q 2014 CHESTERBROOK, Pa., Aug. 7, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. T... 
Printer Friendly Version
Jul 31, 2014Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014
-Company to Host Conference Call That Day at 8:30 a.m. ET- CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the second quarter of 2014 on Thursday, August 7, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the second ... 
Printer Friendly Version
Jul 31, 2014Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan
Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $10 million regulatory milestone payment from its partner Asahi Kasei Pharma Corporation (Asahi Kasei). The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical and Me... 
Printer Friendly Version
Jun 26, 2014Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT
Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company Canadian-Domiciled Structure Creates Stronger Financial Position, Competitive Partnering and M&A Platform Platform Enables Continued Product and Therapeutic Diversification; Expands Geographic Footprint CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company... 
Printer Friendly Version
Jun 25, 2014Sobi files for EU approval of Xiapex for Peyronies disease
STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The Investigation... 
Printer Friendly Version
Jun 11, 2014Auxilium Pharmaceuticals, Inc. Announces Launch Of Authorized Generic Version Of Testim (Testosterone Gel)
CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat adult male... 
Printer Friendly Version
Jun 2, 2014Auxilium Pharmaceuticals, Inc. Announces Departure of Chief Financial Officer
CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. "The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams, Chief Exe... 
Printer Friendly Version
May 30, 2014Auxilium Pharmaceuticals, Inc. To Present At The Jefferies Healthcare Conference
CHESTERBROOK, Pa., May 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Jefferies Healthcare Conference to be held June 2-5, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio Company at 10:00 a.m. ET on Tuesday, June 3, 2014. ... 
Printer Friendly Version
May 19, 2014Auxilium Pharmaceuticals, Inc. Presents New Analyses Of XIAFLEX Peyronie's Disease Data At Urology Meeting
Four Podium Sessions Highlight New Analyses of Data Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., May 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLE... 
Printer Friendly Version
May 12, 2014Auxilium Pharmaceuticals, Inc. To Present At The UBS Healthcare Conference
CHESTERBROOK, Pa., May 12, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the UBS Healthcare Conference to be held May 19-21, 2014 at the Sheraton Times Square in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 11:00 a.m. ET on Monday, Ma... 
Printer Friendly Version
May 7, 2014Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch Healthcare Conference
CHESTERBROOK, Pa., May 7, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9:20 a.... 
Printer Friendly Version
May 5, 2014Auxilium Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
1Q 2014 Net Revenues Increased 34% Over 1Q 2013 to $88.5 Million on Acquisition Growth and Launch Momentum for STENDRA and XIAFLEX in Peyronie's Disease CHESTERBROOK, Pa., May 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and... 
Printer Friendly Version
May 1, 2014Auxilium Pharmaceuticals, Inc. to Present at the Deutsche Bank Healthcare Conference
CHESTERBROOK, Pa., May 1, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m. ET on Thurs... 
Printer Friendly Version
Apr 29, 2014Auxilium Pharmaceuticals, Inc. Lowers 2014 Financial Guidance
Company to Report Full 1Q 2014 Financial Results on Monday, May 5 CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim® testosterone gel. Auxilium's revised financial guidance is as follows ($ millions): Revised Original ... 
Printer Friendly Version
Apr 28, 2014Auxilium Pharmaceuticals, Inc. Announces Presentation Of Data For XIAFLEX At Urology Meeting
Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., April 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be present... 
Printer Friendly Version
Apr 14, 2014Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These ... 
Printer Friendly Version
Apr 7, 2014Sobi Becomes Market Authorisation Holder For Xiapex in Europe
STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced  that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients w... 
Printer Friendly Version
Mar 4, 2014Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday,... 
Printer Friendly Version
Feb 28, 2014Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues FY 2013 Non-GAAP EPS Grew 77% to $0.62 2014 Guidance for Net Revenues of $450 - $490 Million CHESTERBROOK, Pa., Feb. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory a... 
Printer Friendly Version
Feb 25, 2014Auxilium Pharmaceuticals, Inc. To Present At The Cowen And Company Annual Healthcare Conference
CHESTERBROOK, Pa., Feb. 25, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Cowen and Company 34th Annual Healthcare Conference to be held March 3-5, 2014 at the Boston Marriott Copley Place Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its produ... 
Printer Friendly Version
Feb 24, 2014Auxilium Pharmaceuticals, Inc. Announces The FDA Acceptance Of Application Requesting Approval Of XIAFLEX® For The Concurrent Treatment Of Multiple Palpable Cords
PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., Feb. 24, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of a supplemental Biologics License Application (sBLA) requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two  Dupuytren's contracture (DC) cords conc... 
Printer Friendly Version
Feb 21, 2014Auxilium Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2013 Results On February 28, 2014
-Company to Host Conference Call That Day at 9 a.m. ET- CHESTERBROOK, Pa., Feb. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the fourth quarter and full year 2013 on Friday, February 28, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 9 a.m. ET to discuss results and highlights of the f... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Present At The RBC Capital Markets Healthcare Conference
CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the RBC Capital Markets Healthcare Conference to be held February 25-26, 2014 at the New York Palace Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 1:35 ... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Ring the NASDAQ Stock Market Opening Bell On February 26, 2014
-Company Marks Milestone of Two New Product Launches- CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on February 26, 2014 to celebrate Auxilium's transformation into a leading men's healthcare company, including two recent launches of new products in men's healthcare, XIAFLEX® (collagenase cl... 
Printer Friendly Version
Feb 5, 2014Auxilium Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference
CHESTERBROOK, Pa., Feb. 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Leerink Swann Global Healthcare Conference to be held February 11-13, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to participate in a discussion about the Company at 10:40 a.m. ET on Wed... 
Printer Friendly Version
Feb 3, 2014Auxilium Pharmaceuticals, Inc. To Present At The BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 3, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the BIO CEO & Investor Conference to be held February 10-11, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9 a.m. ET on M... 
Printer Friendly Version
Jan 21, 2014VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRA™ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the executive management team will participate in the J.P. Morgan 32nd Annual Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 4 p.m. PT on W... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals Presents Interim Data on XIAFLEX® for the Retreatment of Recurring Dupuytren's Contracture at the American Association for Hand Surgery 2014 Annual Meeting
Data Show Recurrent Hand Contractures Treated Successfully in Nearly 90 Percent of Patients; Retreatment Shown to be Well-Tolerated CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX® (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture (DC) and a rec... 
Printer Friendly Version
Dec 20, 2013Auxilium Pharmaceuticals, Inc. Submits Application To The FDA Requesting Approval Of XIAFLEX® For Concurrent Treatment Of Multiple Palpable Cords
sBLA Submitted for Dupuytren's Contracture, a Progressive Hand Disease that Can Present with Multiple Collagen "Cords" That Limit Movement and Function CHESTERBROOK, Pa., Dec. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) requesting approval of XIAFLEX (collagenase clostridium hi... 
Printer Friendly Version
Dec 13, 2013Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
CHESTERBROOK, Pa., Dec. 13, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the first patient was dosed in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome (FSS). FSS can be a prolonged, painful condition of the shoulder in which increased capsular collagen thickening and subsequen... 
Printer Friendly Version
Dec 6, 2013Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX® for the Treatment of Peyronie's Disease
XIAFLEX is First and Only FDA-Approved Treatment Proven Effective for Peyronie's Disease Company to Host Conference Call Today at 1:30 p.m. ET CHESTERBROOK, Pa., Dec. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX® (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease ... 
Printer Friendly Version
Dec 5, 2013Auxilium Pharmaceuticals, Inc. To Present At The Oppenheimer Conference
CHESTERBROOK, Pa., Dec. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Oppenheimer 24th Annual Conference to be held December 10-11, 2013 at the Crown Plaza in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, December 11, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10... 
Printer Friendly Version
Dec 4, 2013Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
CHESTERBROOK, Pa., Dec. 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") announced today that the United States District Court for the District of Delaware ("Court") granted Upsher-Smith Laboratories, Inc.'s ("USL") motion for summary judgment with respect to its attempts to bring a testosterone gel product to market via its 505(b)(2) NDA using Auxilium's Testim® product as its reference listed drug. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881L... 
Printer Friendly Version
Nov 25, 2013Auxilium Pharmaceuticals Presented New Analyses of XIAFLEX® Peyronie's Disease Data at SMSNA Scientific Meeting
- Six abstracts presented throughout meeting - CHESTERBROOK, Pa., Nov. 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, has announced that new and updated data were presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disea... 
Printer Friendly Version
Nov 20, 2013Auxilium Pharmaceuticals, Inc. to Present Data on XIAFLEX® at the Fall Scientific Meeting of the Sexual Medicine Society of North America
-Multiple Studies of XIAFLEX for the Potential Treatment of Peyronie's Disease to be Presented- CHESTERBROOK, Pa., Nov. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease, will be presented at the upcoming 19th Annual Fall Scientific Meeting of the Sexual Medicine ... 
Printer Friendly Version
Nov 18, 2013Auxilium Announces Results Of The XIAFLEX® In Dupuytren's MULTICORD Contracture Trial
- Expects to submit supplemental Biologics License Application to the FDA in the first quarter of 2014 that supports potential labeling expansion for concurrent treatment of multiple palpable cords- CHESTERBROOK, Pa., Nov. 18, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the results of the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study, a... 
Printer Friendly Version
Nov 6, 2013Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
- 3Q13 Total Net Revenues Increased by 52% vs. 3Q12 to $108.1 MM - CHESTERBROOK, Pa., Nov. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the quarter ending September 30, 2013.  The Company also highlighted select commercial, regulatory and clinical development progress in the third quarter of 2013 and updated guidance for full year 2013. (Logo: http://photos.prnewswire.c... 
Printer Friendly Version